Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $11.62 and traded as high as $12.87. Dynavax Technologies shares last traded at $12.62, with a volume of 5,449,688 shares trading hands.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and set a $29.00 price objective on shares of Dynavax Technologies in a report on Friday, November 8th.
Check Out Our Latest Stock Analysis on DVAX
Dynavax Technologies Stock Performance
The stock has a market cap of $1.66 billion, a P/E ratio of 97.16 and a beta of 1.34. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The company's 50-day simple moving average is $12.72 and its 200 day simple moving average is $11.62.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Assenagon Asset Management S.A. purchased a new position in shares of Dynavax Technologies in the 3rd quarter worth about $8,291,000. Entropy Technologies LP purchased a new position in Dynavax Technologies in the third quarter valued at about $462,000. Bank of Montreal Can grew its position in shares of Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company's stock valued at $11,848,000 after acquiring an additional 82,449 shares during the period. Millennium Management LLC purchased a new stake in shares of Dynavax Technologies during the 2nd quarter worth approximately $17,615,000. Finally, AlphaCentric Advisors LLC raised its holdings in shares of Dynavax Technologies by 55.0% in the 3rd quarter. AlphaCentric Advisors LLC now owns 201,500 shares of the biopharmaceutical company's stock worth $2,245,000 after purchasing an additional 71,500 shares during the period. Institutional investors own 96.96% of the company's stock.
About Dynavax Technologies
(
Get Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Read More
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
